Health Care [ 10/12 ] | Health Care Equipment & Supplies [ 56/74 ]
NYSE | Common Stock
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test.
In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders.
Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 16, 25 | 1.09 Increased by +11.22% | 1.07 Increased by +1.87% |
| Jan 22, 25 | 1.34 Increased by +12.61% | 1.34 |
| Oct 16, 24 | 1.21 Increased by +6.14% | 1.20 Increased by +0.83% |
| Jul 18, 24 | 1.14 Increased by +5.56% | 1.10 Increased by +3.64% |
| Apr 17, 24 | 0.98 Decreased by -4.85% | 0.95 Increased by +3.16% |
| Jan 24, 24 | 1.19 Increased by +15.53% | 1.19 |
| Oct 18, 23 | 1.14 Decreased by -0.87% | 1.10 Increased by +3.64% |
| Jul 20, 23 | 1.08 Decreased by -24.48% | 1.05 Increased by +2.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 10.36 B Increased by +3.95% | 1.32 B Increased by +8.16% | Increased by +12.79% Increased by +4.05% |
| Dec 31, 24 | 10.97 B Increased by +7.16% | 9.23 B Increased by +478.98% | Increased by +84.10% Increased by +440.31% |
| Sep 30, 24 | 10.63 B Increased by +4.85% | 1.65 B Increased by +14.62% | Increased by +15.48% Increased by +9.32% |
| Jun 30, 24 | 10.38 B Increased by +4.00% | 1.30 B Decreased by -5.31% | Increased by +12.55% Decreased by -8.95% |
| Mar 31, 24 | 9.96 B Increased by +2.23% | 1.23 B Decreased by -7.06% | Increased by +12.29% Decreased by -9.08% |
| Dec 31, 23 | 10.24 B Increased by +1.49% | 1.59 B Increased by +54.31% | Increased by +15.56% Increased by +52.05% |
| Sep 30, 23 | 10.14 B Decreased by -2.56% | 1.44 B Increased by +0.07% | Increased by +14.16% Increased by +2.70% |
| Jun 30, 23 | 9.98 B Decreased by -11.36% | 1.38 B Decreased by -31.86% | Increased by +13.78% Decreased by -23.13% |